Literature DB >> 16901654

Respondent-driven sampling in the recruitment of illicit stimulant drug users in a rural setting: findings and technical issues.

Jichuan Wang1, Russel S Falck, Linna Li, Ahmmed Rahman, Robert G Carlson.   

Abstract

Increasingly, respondent-driven sampling (RDS) is being applied to study not-in-treatment users of illicit drugs. Although RDS has been successfully applied in recruiting active users in densely-populated, metropolitan areas, its utility with hidden populations in rural areas has yet to be determined. This study critically evaluates the sample of not-in-treatment, illicit stimulant drug users (n=249) recruited from the application of RDS in three rural counties in west-central Ohio. The findings of this study largely support the results of earlier studies in urban areas and suggest that RDS is a useful method of sampling hidden drug using populations in less densely populated rural areas. Some limitations of RDS are also discussed.

Mesh:

Substances:

Year:  2006        PMID: 16901654     DOI: 10.1016/j.addbeh.2006.06.031

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  54 in total

1.  Perceived need for substance abuse treatment among illicit stimulant drug users in rural areas of Ohio, Arkansas, and Kentucky.

Authors:  Russel S Falck; Jichuan Wang; Robert G Carlson; Laura L Krishnan; Carl Leukefeld; Brenda M Booth
Journal:  Drug Alcohol Depend       Date:  2007-07-02       Impact factor: 4.492

2.  Respondent-driven sampling to recruit young adult non-medical users of pharmaceutical opioids: problems and solutions.

Authors:  Raminta Daniulaityte; Russel Falck; Linna Li; Ramzi W Nahhas; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2011-08-31       Impact factor: 4.492

3.  Longitudinal changes in drug use severity and physical health-related quality of life among untreated stimulant users.

Authors:  Tyrone F Borders; Brenda M Booth; Russel S Falck; Carl Leukefeld; Jichuan Wang; Robert G Carlson
Journal:  Addict Behav       Date:  2009-06-06       Impact factor: 3.913

4.  Silence Surrounding Hepatitis C Status in Risk Relationships Among Rural People Who Use Drugs.

Authors:  Megan G Hofmeister; Jennifer R Havens; April M Young
Journal:  J Prim Prev       Date:  2017-10

5.  Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio.

Authors:  Robert G Carlson; Ramzi W Nahhas; Raminta Daniulaityte; Silvia S Martins; Linna Li; Russel Falck
Journal:  Drug Alcohol Depend       Date:  2013-10-23       Impact factor: 4.492

6.  Factors related to psychosocial barriers to drug treatment among Chinese drug users.

Authors:  Brian C Kelly; Tieqiao Liu; Guanbai Zhang; Wei Hao; Jichuan Wang
Journal:  Addict Behav       Date:  2014-04-13       Impact factor: 3.913

7.  Predictors of alcohol use among rural drug users after disclosure of hepatitis C virus status.

Authors:  Dustin B Stephens; Jennifer R Havens
Journal:  J Stud Alcohol Drugs       Date:  2013-05       Impact factor: 2.582

8.  Beliefs and attitudes regarding drug treatment: application of the theory of planned behavior in African-American cocaine users.

Authors:  Brenda M Booth; Katharine E Stewart; Geoffrey M Curran; Ann M Cheney; Tyrone F Borders
Journal:  Addict Behav       Date:  2014-05-28       Impact factor: 3.913

9.  Innovative recruitment using online networks: lessons learned from an online study of alcohol and other drug use utilizing a web-based, respondent-driven sampling (webRDS) strategy.

Authors:  José A Bauermeister; Marc A Zimmerman; Michelle M Johns; Pietreck Glowacki; Sarah Stoddard; Erik Volz
Journal:  J Stud Alcohol Drugs       Date:  2012-09       Impact factor: 2.582

10.  Sex with older partners is associated with primary HIV infection among men who have sex with men in North Carolina.

Authors:  Christopher B Hurt; Derrick D Matthews; Molly S Calabria; Kelly A Green; Adaora A Adimora; Carol E Golin; Lisa B Hightow-Weidman
Journal:  J Acquir Immune Defic Syndr       Date:  2010-06       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.